IGM Biosciences Future Growth
Future criteria checks 2/6
IGM Biosciences is forecast to grow earnings and revenue by 29.8% and 59.3% per annum respectively. EPS is expected to grow by 38% per annum. Return on equity is forecast to be -201.1% in 3 years.
Key information
29.8%
Earnings growth rate
38.0%
EPS growth rate
Biotechs earnings growth | 31.3% |
Revenue growth rate | 59.3% |
Future return on equity | -201.1% |
Analyst coverage | Good |
Last updated | 23 Apr 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 55 | -211 | -207 | -197 | 7 |
12/31/2025 | 12 | -222 | -200 | -191 | 9 |
12/31/2024 | 3 | -200 | -171 | -167 | 9 |
12/31/2023 | 2 | -246 | -205 | -192 | N/A |
9/30/2023 | 2 | -238 | -196 | -182 | N/A |
6/30/2023 | 2 | -234 | -196 | -182 | N/A |
3/31/2023 | 2 | -229 | -29 | -18 | N/A |
12/31/2022 | 1 | -221 | -16 | -6 | N/A |
9/30/2022 | 1 | -219 | -13 | -3 | N/A |
6/30/2022 | 0 | -205 | -6 | 3 | N/A |
3/31/2022 | N/A | -185 | -146 | -136 | N/A |
12/31/2021 | N/A | -165 | -138 | -125 | N/A |
9/30/2021 | N/A | -139 | -131 | -112 | N/A |
6/30/2021 | N/A | -115 | -116 | -93 | N/A |
3/31/2021 | N/A | -95 | -101 | -79 | N/A |
12/31/2020 | N/A | -81 | -85 | -68 | N/A |
9/30/2020 | N/A | -72 | -68 | -57 | N/A |
6/30/2020 | N/A | -61 | -62 | -57 | N/A |
3/31/2020 | N/A | -53 | -56 | -53 | N/A |
12/31/2019 | N/A | -43 | -47 | -45 | N/A |
9/30/2019 | N/A | -37 | -41 | -39 | N/A |
6/30/2019 | N/A | -34 | -31 | -30 | N/A |
3/31/2019 | N/A | -27 | -26 | -24 | N/A |
12/31/2018 | N/A | -23 | -21 | -20 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 1K0 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 1K0 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 1K0 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 1K0's revenue (59.3% per year) is forecast to grow faster than the German market (5.1% per year).
High Growth Revenue: 1K0's revenue (59.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 1K0 is forecast to be unprofitable in 3 years.